DNA Sequencing Reveals Novel Compound Behind Mushroom That Causes Hallucinations of Tiny Humans

Every summer, hospitals in China's Yunnan province brace for an annual influx of patients presenting with a highly specific, bizarre complaint: seeing dozens of tiny, fully autonomous human figures marching across their walls and furniture. One local hospital alone treats hundreds of these cases each year during the peak foraging season between June and August.[1][4]

The culprit is Lanmaoa asiatica, a reddish bolete mushroom known locally as jian shou qing, or "see-hand-blue," because its flesh rapidly oxidizes and changes color when bruised. While it is a prized, umami-rich culinary delicacy when cooked thoroughly for at least 15 minutes, consuming it raw or undercooked reliably triggers a rare neurological phenomenon known as Lilliputian hallucinations.[1][4]

Now, a comprehensive genetic analysis by researchers at the University of Utah has deepened the mystery surrounding the fungus. By sequencing the genomes of 53 distinct mushroom samples from across the wider Lanmaoa genus, the scientific team expected to uncover the genetic signature of a familiar hallucinogen responsible for the visions.[2]

Instead, the sequencing revealed a complete absence of known psychoactive pathways. The analysis confirmed that L. asiatica lacks the genes required to produce psilocybin—the active ingredient in traditional "magic mushrooms"—as well as ibotenic acid and muscimol, the mind-altering compounds found in the iconic red-and-white fly agaric.[1][2][4]

"Biosynthetic gene mining of the L. asiatica genome found no close hits with any genes known in the production of mushroom psychoactive compounds," the researchers noted in their published findings. The results prove that the fungus relies on an entirely novel, unidentified metabolite to induce its powerful mind-altering effects.[2]

The Mechanics of Micropsia

The visions induced by the mushroom are a complex manifestation of micropsia, a visual distortion where objects, animals, or people are perceived as significantly smaller than their actual physical size. The clinical term directly references the six-inch-tall inhabitants of Jonathan Swift's 1726 novel Gulliver's Travels.[1][5]

In standard clinical settings, micropsia often stems from physical changes within the eye itself. When the macula swells or distorts due to edema, macular degeneration, or central serous retinopathy, the physical spacing between retinal photoreceptor cells increases. Because an incoming image covers fewer sensory cells, the brain interprets the object as being miniature.[5]

However, the hallucinations triggered by L. asiatica are neurological rather than optical. The unidentified fungal compound appears to bypass the retina entirely, altering sensory processing directly within the visual cortex. This chemical intervention temporarily mimics the severe sensory disruptions typically seen only in specific psychiatric disorders or localized brain lesions.[4][5]

The physiological onset of the mushroom's effects is unusually delayed compared to typical psychedelics. Patients generally do not experience the Lilliputian visions until 12 to 24 hours after ingestion, and the hallucinations can persist continuously for anywhere from one to seven days, depending on the dosage consumed.[1][4]

A Unique Chemical Signature

Unlike classical psychedelics such as LSD or psilocybin, which produce highly individualized trips heavily influenced by a person's environment, mood, and expectations, L. asiatica acts with mechanical consistency. It triggers the exact same visions of tiny, cartoonish figures across different patients, regardless of their cultural background or physical location.[1][3]

"I don't know of anything else that produces such consistent hallucinations," noted Colin Domnauer, a doctoral researcher in biology at the University of Utah who co-authored the genetic study. The sheer reliability of the effect suggests the compound targets a very specific, isolated neural circuit in the human brain.[1]

During their analysis of the 53 genomic samples, the researchers also mapped the broader evolutionary tree of the fungus. They identified 17 distinct species within the Lanmaoa genus, including four that were previously completely unknown to science. Currently, L. asiatica is the only species in the genus confirmed to possess psychoactive properties.[2]

The physical experience of the intoxication is also distinct from other hallucinogens. Alongside the visual distortions, patients frequently report acute gastrointestinal distress, dizziness, and occasional states of delirium. Despite the intensity of the multi-day hallucinations, patients typically remain aware that the tiny figures are not real, and they recover fully with no lasting toxicity.[1][4]

The evolutionary purpose of this novel compound remains entirely unknown. While many fungi produce toxins to deter predators or inhibit competing organisms, the specific chemical structure that happens to trigger micropsia in the human brain appears to be an accidental byproduct of the mushroom's unique biochemistry.[2][4]

A Window Into Visual Processing

Researchers believe that isolating and synthesizing this novel compound could provide a powerful new pharmacological tool for neuroscience. Lilliputian hallucinations are not exclusive to mushroom poisoning; they are a documented clinical symptom in several severe neurological conditions that currently lack effective treatments.[4]

Patients suffering from Charles Bonnet syndrome—a condition where vision loss triggers phantom images—frequently report seeing miniature figures. Similar microptic hallucinations are also documented in advanced Parkinson's disease, macular degeneration, and the delirium tremens associated with severe alcohol withdrawal.[4][5]

Currently, medical science lacks a reliable way to model or induce these specific visual distortions in a controlled laboratory setting. Because L. asiatica triggers the phenomenon so consistently, its active compound could allow researchers to map the exact neural pathways responsible for scale perception and internal image generation.[1][4]

The University of Utah team's next objective is to isolate the specific metabolite from the mushroom's tissue and determine its exact chemical structure. By understanding how the compound alters the visual cortex, scientists hope to eventually develop targeted treatments for the disruptive hallucinations that accompany degenerative brain diseases.[2][4]